Is LB Pharmaceuticals Inc Common Stock (LBRX) a Buy, Sell, or Hold?
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$32.02 USD
-$0.23 (-0.71%)
- Volume
- 210.72K
- Average Volume
- 259.27K
- Market Capitalization
- $918.23M
- P/E Ratio
- -1.49
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $35.35
- Year Low
- $13.36
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $35.68
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Heather D. Turner |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | LBRX |
| CUSIP | 50180M108 |
| CIK | 0001691082 |
| Web | https://lbpharma.us |
| Phone | 212 605 0300 |
| Currency | USD |
| Employees | 27 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 35.68 |
| Quick Ratio | 35.68 |
| Cash Ratio | 29.40 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.79 |
| Price / Cash Flow | -18.21 |
| Price / Book | 2.39 |
Price Target and Rating
| Average Stock Price Forecast | $40.00 |
| High Stock Price Forecast | $45.00 |
| Low Stock Price Forecast | $36.00 |
| Forecast Upside/Downside | -19.95% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 1 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1 |
| Trailing P/E Ratio | -1.49 |
| PEG Ratio | 0.09 |
| P/E Growth | 0.09 |
| Net Income | $-25.2M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -17.68% |
| Return on Assets | -9.95% |
Financials Score
| AltmanZ Score | 37.82 |
| Piotroski Score | 1.00 |
| Working Capital | 378.17M |
| Total Assets | 393.48M |
| Ebit | -39.38M |
| Market Cap | 924.82M |
| Total Liabilities | 14.79M |
Poll Results
About LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) Stock
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride. ...
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 16:38:00
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior Vice President, Clinical Operations of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on July 10, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Zergebel entering into employment with LB Pharmaceuticals.
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
2026-06-30 08:00:00
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. Mr. Zergebel, a seasoned biotechnology executive with more than 25 years of global development operations experience, brings deep expertise in growing and leading cross-functional teams including clinical operations, data management, and project and portfolio management.
LB Pharmaceuticals to Participate in Upcoming June Investor Events
2026-05-28 16:05:00
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that members of its executive team, will present and participate in the following upcoming investor conferences:
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
2026-05-26 13:00:20
LB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 16:05:00
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and marketable securities of $365.
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 16:05:00
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression
2026-04-22 16:05:00
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the publication in the Journal of the American Medical Association (JAMA) Psychiatry of its manuscript titled “Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults with Acute Schizophrenia: A Phase 2 Randomized Clinical Trial.” LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT-7 receptors that is being advanced as a potential first benzamide in the U.S. for the treatment of neuropsychiatric disorders.
2026-04-17 20:11:48
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Frequently Asked Questions
-
What is the current LB Pharmaceuticals Inc Common Stock (LBRX) stock price?
-
LB Pharmaceuticals Inc Common Stock(NASDAQ:LBRX) stock price is $32.02 in the last trading session. During the trading session, LBRX stock reached the peak price of $35.345 while $13.36 was the lowest point it dropped to. The percentage change in LBRX stock occurred in the recent session was --0.71% while the dollar amount for the price change in LBRX stock was -$-0.23.
-
LBRX's industry and sector of operation?
-
The NASDAQ listed LBRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LBRX?
-
Anna Eramo | Advisor
James Rawls | Senior Vice President of Regulatory Affairs
Richard Silva | Senior Vice President of Technical Operations
Soffer | Chief Operating & Business Officer
Marc L. Panoff | Senior Vice President of Finance -
How many employees does LBRX have?
-
Number of LBRX employees currently stands at 27. LBRX operates from One Pennsylvania Plaza, New York, NY 10119, US.
-
Link for LBRX official website?
-
Official Website of LBRX is: https://lbpharma.us
-
How do I contact LBRX?
-
LBRX could be contacted at phone #212 605 0300 and can also be accessed through its website. LBRX operates from One Pennsylvania Plaza, New York, NY 10119, US.
-
How many shares of LBRX are traded daily?
-
The average number of LBRX shares traded daily for last 3 months was 259.27K.
-
What is the market cap of LBRX currently?
-
The market value of LBRX currently stands at $918.23M with its latest stock price at $32.02